Intake of stigmasterol and β-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet.

Intake of stigmasterol and β-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet.
复制标题

DOI:
10.1016/j.bbalip.2018.08.004
复制
发表时间:
2018-10
期刊:
Biochimica et biophysica acta. Molecular and cell biology of lipids
影响因子:
--
通讯作者:
Yang CS
Yang CS
中科院分区:
其他
文献类型:
--
作者:
Feng S;Dai Z;Liu AB;Huang J;Narsipur N;Guo G;Kong B;Reuhl K;Lu W;Luo Z;Yang CS

文献摘要

参考文献

被引文献

相似文献

研究并比较两种常见膳食植物甾醇(豆甾醇和 β-谷甾醇)在改变脂质代谢和减轻非酒精性脂肪肝 (NAFLD) 方面的作用。在高脂西式饮食 (HFWD) 中向小鼠施用 0.4% 的豆甾醇和 β-谷甾醇,为期 17 周。豆甾醇和β-谷甾醇可显着改善 HFWD 诱导的脂肪肝和代谢异常,包括肝脏总脂质、三酰甘油、胆固醇和肝脏组织病理学水平升高。两种植物甾醇都能降低肠道胆汁酸的水平,同时粪便脂质水平显着增加。此外,他们还改变了参与脂质代谢的基因的表达。 β-谷甾醇对大多数这些参数的影响效果较差。肝脏和血清样本的脂质组学分析表明,豆甾醇可防止 HFWD 诱导的某些二酰基甘油和三酰基甘油种类的升高以及某些磷脂种类的降低。豆甾醇还降低神经酰胺的血清水平。豆甾醇和 β-谷甾醇的剂量与 FDA 建议的人体降低胆固醇水平相当,可缓解 HFWD 诱发的 NAFLD。豆甾醇比β-谷甾醇更有效,可能是因为它抑制肝脏脂肪生成基因表达并调节循环神经酰胺水平。
To investigate and compare the effects of two common dietary phytosterols, stigmasterol and β-sitosterol, in altering lipid metabolism and attenuating nonalcoholic fatty liver disease (NAFLD). Stigmasterol and β-sitosterol were administered to mice at 0.4% in a high-fat western-style diet (HFWD) for 17 weeks. Stigmasterol and β-sitosterol significantly ameliorated HFWD-induced fatty liver and metabolic abnormalities, including elevated levels of hepatic total lipids, triacylglycerols, cholesterol and liver histopathology. Both phytosterols decreased the levels of intestinal bile acids, accompanied by markedly increased fecal lipid levels. In addition, they altered the expression of genes involved in lipid metabolism. β-Sitosterol was less effective in affecting most of these parameters. Lipidomic analysis of liver and serum samples showed that stigmasterol prevented the HFWD-induced elevation of some di- and triacylglycerol species and lowering of some phospholipid species. Stigmasterol also decreased serum levels of ceramides. Stigmasterol and β-sitosterol, at a dose corresponding to that suggested for humans by the FDA for lowering cholesterol levels, are shown to alleviate HFWD-induced NAFLD. Stigmasterol was more effective than β-sitosterol, possibly because of its suppression of hepatic lipogenic gene expression and modulation of circulating ceramide levels.
DOI: 10.1016/s0248-4900(05)80176-5
发表时间: 1993-01-01
影响因子: 2.7
作者:
DREYER, C;KELLER, H;WAHLI, W
通讯作者: WAHLI, W
西式高脂饮食诱导的肥胖相关性非酒精性脂肪肝小鼠模型的代谢表型及脂肪和肝脏特征
DOI: 10.1152/ajpendo.00319.2015
发表时间: 2016-03-15
影响因子: 5.1
作者:
Luo, Yuwen;Burrington, Christine M.;Greene, Michael W.
通讯作者: Greene, Michael W.
DOI: 10.1021/jf2029016
发表时间: 2011-11-09
影响因子: 6.1
作者:
Chen YK;Cheung C;Reuhl KR;Liu AB;Lee MJ;Lu YP;Yang CS
通讯作者: Yang CS
DOI: 10.1371/journal.pone.0022775
发表时间: 2011
期刊: PloS one
影响因子: 3.7
作者:
Gorden DL;Ivanova PT;Myers DS;McIntyre JO;VanSaun MN;Wright JK;Matrisian LM;Brown HA
通讯作者: Brown HA
DOI: 10.1194/jlr.r800080-jlr200
发表时间: 2009-04-01
影响因子: 6.5
作者:
Bartke, Nana;Hannun, Yusuf A.
通讯作者: Hannun, Yusuf A.